Sang-Ick Chang
Family Practice · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Research they published
14 papers · cited 119 times
Published as Sang-ick Chang at Stanford Health Care, Stanford Medicine.
Research identity is not a guarantee of current clinical practice. Same name is not the same person — if this looks like someone else, tell us.
| 2026 | A mixed methods evaluation of a six-year primary care community safety net-academic partnership model | Academic Medicine |
| 2022 | A value-based approach to optimize red blood cell transfusion in patients receiving extracorporeal membrane oxygenation | Perfusion |
| 2021 | Case-control study evaluating risk factors for SARS-CoV-2 outbreak amongst healthcare personnel at a tertiary care center | American Journal of Infection Control |
| 2021 | Building Bridges Between Community Health Centers and Academic Medical Centers in a COVID-19 Pandemic | The Journal of the American Board of Family Medicine |
| 2021 | The prevalence of COVID-19 in healthcare personnel in an adult and pediatric academic medical center | American Journal of Infection Control |
| 2020 | Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence in healthcare personnel in northern California early in the coronavirus disease 2019 (COVID-19) pandemic | Infection Control and Hospital Epidemiology |
See all 14 papers
| 2020 | Large-Scale Testing of Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2 | Emerging infectious diseases |
| 2018 | Primary Care 2.0 | American Journal of Medical Quality |
| 2017 | Patient and provider perspectives on the development of personalized medicine: a mixed-methods approach | Journal of Community Genetics |
| 2009 | Bag the old excuses. Simple, cheap changes can improve quality.First author | PubMed |
| 2002 | Clinical inquiries. What is the most effective treatment for acute low back pain?Last author | PubMed |
| 2001 | Clinical inquiries. What is the best approach to prevention and treatment of osteoporosis?Last author | PubMed |
| 2001 | Clinical inquiries. What is the best approach to the evaluation and treatment of chronic cough?Last author | PubMed |
| 2001 | Clinical inquiries. What is the best test to diagnose urinary tract stones?Last author | PubMed |
Topics: COVID-19 epidemiological studies · Primary Care and Health Outcomes · Community Health and Development · Healthcare Quality and Management · COVID-19 Clinical Research Studies
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Sang-Ick Chang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G64586 · Current
Licensed to practise in California · since 1988 · expires 2028-09-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$17,497
Medicare paid this office $17,497 for 141 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 78 | $4,757 | $61 |
| Return visit (30+ min) | 61 | $4,131 | $49 |
| Short return visit (20+ min) | 42 | $2,626 | $48 |
| Long return visit (40+ min) | 22 | $1,966 | $68 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 66 | $1,380 | $15 |
See all 6 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 78 | $4,757 | $61 |
| Return visit (30+ min) | 61 | $4,131 | $49 |
| Short return visit (20+ min) | 42 | $2,626 | $48 |
| Long return visit (40+ min) | 22 | $1,966 | $68 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 66 | $1,380 | $15 |
| Short return visit | 15 | $793 | $44 |
Who their Medicare patients are
141 Original Medicare patients in 2024. Average age 76 · Women 33% · Also on Medicaid 9% · Health risk score 0.95. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 59% · Coronary heart disease 18% · Diabetes 16% · Cancer 13% · Atrial fibrillation 13% · Chronic kidney disease 11% · Depression 11% · Heart failure 9%.
The office billed $108,250, Medicare allowed $25,227 and paid $17,497; for 386 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 141 | 386 | 76 | 0.95 | $108,250 | $17,497 |
| 2023 | 122 | 226 | 78 | 0.90 | $79,106 | $13,868 |
| 2022 | 126 | 271 | 77 | 0.93 | $87,773 | $14,783 |
| 2021 | 124 | 276 | 77 | 1.01 | $103,781 | $16,157 |
| 2020 | 112 | 240 | 76 | 1.03 | $69,597 | $14,783 |
| 2019 | 120 | 290 | 77 | 1.04 | $52,129 | $18,852 |
| 2018 | 121 | 278 | 76 | 1.09 | $42,444 | $16,779 |
| 2017 | 118 | 281 | 76 | 1.21 | $56,707 | $17,409 |
| 2016 | 85 | 195 | 77 | 1.28 | $38,565 | $11,566 |
| 2015 | 87 | 205 | 75 | 1.10 | $37,992 | $11,902 |
| 2014 | 81 | 211 | 76 | 1.24 | $39,751 | $11,850 |
| 2013 | 49 | 149 | 75 | 1.01 | $28,454 | $8,496 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 74 | $4,784 | $65 |
| Return visit (30+ min) | 46 | $3,329 | $57 |
| Short return visit (20+ min) | 37 | $1,995 | $46 |
| Long return visit (40+ min) | 17 | $1,782 | $81 |
2022: 5 services
| Return visit (30+ min) | 59 | $4,089 | $55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 64 | $3,572 | $56 |
| Short return visit (20+ min) | 42 | $2,980 | $49 |
| Long return visit (40+ min) | 13 | $848 | $50 |
| Short return visit | 17 | $693 | $38 |
2021: 5 services
| Return visit (30+ min) | 50 | $4,142 | $56 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 71 | $3,641 | $51 |
| Short return visit (20+ min) | 39 | $2,762 | $49 |
| Long return visit (40+ min) | 22 | $2,379 | $77 |
| Short return visit | 18 | $1,056 | $46 |
2020: 5 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 32 | $4,485 | $140 |
| Return visit (30+ min) | 49 | $4,046 | $60 |
| Short return visit (20+ min) | 48 | $2,747 | $40 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $697 | $41 |
| Short return visit | 23 | $583 | $19 |
2019: 4 services
| Return visit (30+ min) | 55 | $5,637 | $63 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 38 | $5,285 | $139 |
| Short return visit (20+ min) | 71 | $4,765 | $41 |
| Short return visit | 14 | $366 | $20 |
2018: 4 services
| Return visit (30+ min) | 71 | $7,486 | $59 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $3,319 | $138 |
| Short return visit (20+ min) | 54 | $3,101 | $37 |
| Short return visit | 14 | $315 | $23 |
2017: 3 services
| Return visit (30+ min) | 70 | $8,012 | $57 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 27 | $3,726 | $138 |
| Short return visit (20+ min) | 47 | $3,110 | $42 |
2016: 4 services
| Return visit (30+ min) | 42 | $4,399 | $65 |
| Short return visit (20+ min) | 48 | $2,691 | $38 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | $1,664 | $139 |
| Short return visit | 12 | $246 | $18 |
2015: 3 services
| Return visit (30+ min) | 44 | $5,056 | $61 |
| Short return visit (20+ min) | 41 | $3,099 | $44 |
| Short return visit | 15 | $227 | $15 |
2014: 4 services
| Return visit (30+ min) | 41 | $5,005 | $60 |
| Short return visit (20+ min) | 43 | $3,370 | $42 |
| New patient visit (45+ min) | 12 | $986 | $82 |
| Short return visit | 11 | $268 | $22 |
2013: 3 services
| Short return visit (20+ min) | 29 | $3,350 | $43 |
| New patient visit (45+ min) | 21 | $1,916 | $91 |
| Return visit (30+ min) | 18 | $1,775 | $63 |
Medicaid work
$8,360 in 2022
Medicaid paid $8,360 for 209 billed services this clinician did in 2022, up to 70 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose | 70 | $2,800 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 54 | $2,160 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose | 43 | $1,720 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose | 29 | $1,160 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 13 | $520 |
| 2022 | 209 | 5 | 70 | $8,360 |
| 2021 | 2,105 | 8 | 339 | $77,346 |
See the largest Medicaid services in earlier years
2021
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose | 662 | $25,408 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose | 646 | $21,172 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 261 | $9,610 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 228 | $8,836 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose | 121 | $4,840 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 86 | $3,440 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 56 | $2,240 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 45 | $1,800 |
Drugs they prescribed that Part D paid
$107,184
Pharmacies billed $107,184 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,043 generic and fewer than 11 brand-name prescriptions · $107,184 in drug cost · 23 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 23 | $26,344 | $1,145 |
| Ozempic | 23 | $22,944 | $998 |
| Atorvastatin | 126 | $1,245 | $10 |
| Finasteride | 67 | $1,179 | $18 |
| Tamsulosin | 43 | $1,016 | $24 |
See all 22 drugs
| Eliquis | 23 | $26,344 | $1,145 |
| Ozempic | 23 | $22,944 | $998 |
| Atorvastatin | 126 | $1,245 | $10 |
| Finasteride | 67 | $1,179 | $18 |
| Tamsulosin | 43 | $1,016 | $24 |
| Omeprazole | 35 | $570 | $16 |
| Chlorthalidone | 24 | $546 | $23 |
| Losartan | 48 | $489 | $10 |
| Levothyroxine | 45 | $466 | $10 |
| Metoprolol | 32 | $440 | $14 |
| Amlodipine Besylate | 64 | $394 | $6 |
| Lisinopril | 37 | $386 | $10 |
| Rosuvastatin | 23 | $356 | $15 |
| Losartan-Hydrochlorothiazide | 36 | $338 | $9 |
| Escitalopram | 13 | $259 | $20 |
| Alendronate | 26 | $246 | $9 |
| Venlafaxine Hcl Er | 20 | $243 | $12 |
| Gabapentin | 25 | $201 | $8 |
| Timolol Maleate | 12 | $192 | $16 |
| Hydrochlorothiazide | 24 | $173 | $7 |
| Metformin | 18 | $161 | $9 |
| Atenolol | 16 | $138 | $9 |
Year by year
| 2024 | 1,173 | 118 | None | None | $107,184 |
| 2023 | 1,098 | 126 | None | None | $96,118 |
| 2022 | 1,138 | 128 | 0% (0) | None | $100,962 |
| 2021 | 1,153 | 120 | None | 9% | $95,062 |
| 2020 | 1,197 | 128 | None | 12% | $103,205 |
| 2019 | 1,108 | 116 | None | None | $79,275 |
| 2018 | 1,330 | 115 | 1% (13) | None | $106,909 |
| 2017 | 1,181 | 105 | 3% (29) | None | $65,776 |
| 2016 | 947 | 79 | 1% (11) | 18% | $54,501 |
| 2015 | 854 | 65 | None | None | $72,854 |
| 2014 | 662 | 61 | None | None | $50,668 |
| 2013 | 194 | 34 | None | None | $5,763 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Eliquis | 23 | $28,009 | $1,218 |
| Synthroid | 11 | $1,515 | $138 |
| Atorvastatin | 134 | $1,510 | $11 |
| Chlorthalidone | 25 | $1,176 | $47 |
| Losartan | 78 | $1,006 | $13 |
| Tamsulosin | 46 | $1,003 | $22 |
| Levothyroxine | 54 | $921 | $17 |
| Metoprolol | 44 | $677 | $15 |
| Amlodipine Besylate | 79 | $547 | $7 |
| Omeprazole | 19 | $409 | $22 |
| Finasteride | 30 | $284 | $9 |
| Rosuvastatin | 15 | $276 | $18 |
| Losartan-Hydrochlorothiazide | 28 | $261 | $9 |
| Alendronate | 22 | $234 | $11 |
| Lisinopril | 37 | $211 | $6 |
| Escitalopram | 14 | $206 | $15 |
| Triamcinolone Acetonide | 16 | $198 | $12 |
| Metformin | 25 | $195 | $8 |
| Allopurinol | 13 | $190 | $15 |
| Gabapentin | 12 | $178 | $15 |
| Hydrochlorothiazide | 19 | $120 | $6 |
| Simvastatin | 12 | $70 | $6 |
| Atenolol | 17 | $64 | $4 |
| Sildenafil Citrate | 13 | $46 | $4 |
2022: 25 drugs
| Eliquis | 27 | $31,383 | $1,162 |
| Jardiance | 13 | $10,357 | $797 |
| Atorvastatin | 149 | $1,943 | $13 |
| Synthroid | 12 | $1,685 | $140 |
| Tamsulosin | 43 | $1,422 | $33 |
| Levothyroxine | 60 | $1,141 | $19 |
| Losartan | 82 | $1,128 | $14 |
| Metoprolol | 44 | $1,030 | $23 |
| Chlorthalidone | 14 | $797 | $57 |
| Finasteride | 32 | $758 | $24 |
| Amlodipine Besylate | 84 | $691 | $8 |
| Lisinopril | 53 | $600 | $11 |
| Metformin | 34 | $486 | $14 |
| Escitalopram | 19 | $478 | $25 |
| Pantoprazole | 11 | $459 | $42 |
| Carvedilol | 12 | $426 | $35 |
| Hydrochlorothiazide | 32 | $392 | $12 |
| Alendronate | 22 | $376 | $17 |
| Losartan-Hydrochlorothiazide | 28 | $358 | $13 |
| Gabapentin | 14 | $276 | $20 |
| Omeprazole | 15 | $269 | $18 |
| Allopurinol | 15 | $187 | $12 |
| Triamcinolone Acetonide | 15 | $164 | $11 |
| Metformin Hcl Er | 14 | $78 | $6 |
| Atenolol | 11 | $53 | $5 |
2021: 24 drugs
| Eliquis | 23 | $22,860 | $994 |
| Atorvastatin | 148 | $2,189 | $15 |
| Tamsulosin | 58 | $2,124 | $37 |
| Synthroid | 16 | $2,007 | $125 |
| Chlorthalidone | 22 | $1,146 | $52 |
| Levothyroxine | 51 | $1,121 | $22 |
| Metoprolol | 44 | $1,098 | $25 |
| Finasteride | 38 | $1,069 | $28 |
| Losartan | 60 | $955 | $16 |
| Lisinopril | 65 | $780 | $12 |
| Metformin | 42 | $547 | $13 |
| Pantoprazole | 12 | $534 | $44 |
| Amlodipine Besylate | 68 | $488 | $7 |
| Escitalopram | 17 | $354 | $21 |
| Alendronate | 29 | $311 | $11 |
| Losartan-Hydrochlorothiazide | 20 | $309 | $15 |
| Gabapentin | 13 | $276 | $21 |
| Hydrochlorothiazide | 40 | $274 | $7 |
| Carvedilol | 14 | $246 | $18 |
| Allopurinol | 14 | $200 | $14 |
| Doxazosin Mesylate | 11 | $198 | $18 |
| Omeprazole | 11 | $189 | $17 |
| Simvastatin | 13 | $186 | $14 |
| Metformin Hcl Er | 13 | $121 | $9 |
2020: 23 drugs
| Eliquis | 21 | $20,144 | $959 |
| Wixela Inhub | 11 | $3,421 | $311 |
| Atorvastatin | 146 | $2,883 | $20 |
| Metoprolol | 61 | $2,030 | $33 |
| Tamsulosin | 42 | $1,587 | $38 |
| Levothyroxine | 57 | $1,562 | $27 |
| Synthroid | 11 | $1,342 | $122 |
| Chlorthalidone | 23 | $1,325 | $58 |
| Losartan | 72 | $1,229 | $17 |
| Lisinopril | 64 | $931 | $15 |
| Finasteride | 30 | $585 | $20 |
| Amlodipine Besylate | 77 | $544 | $7 |
| Hydrochlorothiazide | 53 | $456 | $9 |
| Irbesartan | 12 | $386 | $32 |
| Gabapentin | 26 | $368 | $14 |
| Alendronate | 28 | $337 | $12 |
| Escitalopram | 17 | $326 | $19 |
| Carvedilol | 15 | $285 | $19 |
| Metformin | 25 | $251 | $10 |
| Metformin Hcl Er | 14 | $141 | $10 |
| Furosemide | 14 | $118 | $8 |
| Atenolol | 12 | $107 | $9 |
| Metoprolol | 13 | $81 | $6 |
2019: 19 drugs
| Metoprolol | 58 | $3,472 | $60 |
| Atorvastatin | 132 | $3,131 | $24 |
| Tamsulosin | 42 | $1,782 | $42 |
| Chlorthalidone | 25 | $1,592 | $64 |
| Finasteride | 26 | $1,125 | $43 |
| Levothyroxine | 35 | $1,035 | $30 |
| Amlodipine Besylate | 79 | $788 | $10 |
| Losartan | 46 | $712 | $15 |
| Valsartan | 12 | $709 | $59 |
| Lisinopril | 54 | $686 | $13 |
| Duloxetine | 16 | $482 | $30 |
| Alendronate | 31 | $399 | $13 |
| Gabapentin | 16 | $396 | $25 |
| Metformin | 29 | $382 | $13 |
| Hydrochlorothiazide | 42 | $372 | $9 |
| Glimepiride | 18 | $299 | $17 |
| Simvastatin | 15 | $175 | $12 |
| Metformin Hcl Er | 13 | $154 | $12 |
| Atenolol | 17 | $129 | $8 |
2018: 34 drugs
| Januvia | 15 | $18,648 | $1,243 |
| Viread | 12 | $13,204 | $1,100 |
| Advair Diskus | 16 | $9,806 | $613 |
| Atorvastatin | 129 | $3,182 | $25 |
| Levothyroxine | 45 | $1,490 | $33 |
| Metoprolol | 35 | $1,431 | $41 |
| Cholestyramine Light | 13 | $1,400 | $108 |
| Proair Hfa | 15 | $1,070 | $71 |
| Warfarin | 12 | $1,018 | $85 |
| Tamsulosin | 30 | $976 | $33 |
| Valsartan | 19 | $912 | $48 |
| Amlodipine Besylate | 98 | $896 | $9 |
| Ventolin Hfa | 16 | $876 | $55 |
| Chlorthalidone | 16 | $860 | $54 |
| Lisinopril | 70 | $727 | $10 |
| Finasteride | 19 | $626 | $33 |
| Omeprazole | 25 | $616 | $25 |
| Metformin | 44 | $536 | $12 |
| Proctozone-Hc | 13 | $509 | $39 |
| Hydrochlorothiazide | 56 | $475 | $8 |
| Losartan | 38 | $456 | $12 |
| Glimepiride | 15 | $438 | $29 |
| Terazosin | 13 | $390 | $30 |
| Mirtazapine | 11 | $357 | $32 |
| Alendronate | 41 | $348 | $8 |
| Pravastatin | 17 | $327 | $19 |
| Fluconazole | 13 | $312 | $24 |
| Triamterene-Hydrochlorothiazid | 16 | $243 | $15 |
| Losartan-Hydrochlorothiazide | 12 | $195 | $16 |
| Hydrocodone-Acetaminophen | 12 | $188 | $16 |
| Fluticasone Propionate | 14 | $171 | $12 |
| Atenolol | 20 | $169 | $8 |
| Simvastatin | 18 | $163 | $9 |
| Metoprolol | 16 | $159 | $10 |
2017: 30 drugs
| Advair Diskus | 24 | $8,885 | $370 |
| Atorvastatin | 110 | $2,556 | $23 |
| Proair Hfa | 31 | $1,811 | $58 |
| Metoprolol | 37 | $1,378 | $37 |
| Valsartan | 29 | $1,354 | $47 |
| Ketoconazole | 13 | $1,203 | $93 |
| Levothyroxine | 36 | $1,151 | $32 |
| Chlorthalidone | 12 | $747 | $62 |
| Tamsulosin | 22 | $701 | $32 |
| Doxazosin Mesylate | 12 | $650 | $54 |
| Lisinopril | 53 | $494 | $9 |
| Amlodipine Besylate | 69 | $474 | $7 |
| Valsartan-Hydrochlorothiazide | 15 | $434 | $29 |
| Glimepiride | 16 | $410 | $26 |
| Metformin | 50 | $406 | $8 |
| Diphenoxylate-Atropine | 11 | $387 | $35 |
| Gabapentin | 21 | $351 | $17 |
| Proctozone-Hc | 11 | $293 | $27 |
| Hydrochlorothiazide | 42 | $289 | $7 |
| Alendronate | 42 | $284 | $7 |
| Losartan | 36 | $276 | $8 |
| Atenolol | 25 | $262 | $10 |
| Hydrocodone-Acetaminophen | 18 | $240 | $13 |
| Terazosin | 11 | $231 | $21 |
| Omeprazole | 25 | $188 | $8 |
| Losartan-Hydrochlorothiazide | 14 | $186 | $13 |
| Metoprolol | 14 | $161 | $11 |
| Fluconazole | 12 | $133 | $11 |
| Pravastatin | 13 | $124 | $10 |
| Furosemide | 12 | $19 | $2 |
2016: 29 drugs
| Advair Diskus | 22 | $8,002 | $364 |
| Nasonex | 13 | $3,107 | $239 |
| Valsartan | 15 | $1,994 | $133 |
| Atorvastatin | 78 | $1,730 | $22 |
| Levothyroxine | 60 | $1,415 | $24 |
| Tamsulosin | 21 | $1,068 | $51 |
| Valsartan-Hydrochlorothiazide | 18 | $1,013 | $56 |
| Proair Hfa | 16 | $865 | $54 |
| Chlorthalidone | 14 | $858 | $61 |
| Metoprolol | 24 | $778 | $32 |
| Bupropion Xl | 11 | $526 | $48 |
| Cholestyramine Light | 12 | $440 | $37 |
| Proctozone-Hc | 11 | $436 | $40 |
| Amlodipine Besylate | 58 | $429 | $7 |
| Alendronate | 36 | $370 | $10 |
| Lisinopril | 42 | $352 | $8 |
| Metformin | 25 | $345 | $14 |
| Enalapril Maleate | 18 | $336 | $19 |
| Omeprazole | 27 | $258 | $10 |
| Losartan | 25 | $225 | $9 |
| Atenolol | 22 | $204 | $9 |
| Fluconazole | 13 | $176 | $14 |
| Glimepiride | 17 | $166 | $10 |
| Simvastatin | 11 | $138 | $13 |
| Metoprolol | 11 | $128 | $12 |
| Lisinopril-Hydrochlorothiazide | 11 | $71 | $6 |
| Citalopram Hbr | 11 | $45 | $4 |
| Hydrochlorothiazide | 12 | $43 | $4 |
| Furosemide | 13 | $39 | $3 |
2015: 29 drugs
| Advair Diskus | 14 | $6,619 | $473 |
| Xarelto | 15 | $4,821 | $321 |
| Nasonex | 15 | $3,118 | $208 |
| Uloric | 12 | $3,045 | $254 |
| Levothyroxine | 54 | $1,540 | $29 |
| Fluvastatin | 11 | $1,226 | $111 |
| Atorvastatin | 43 | $1,060 | $25 |
| Proair Hfa | 17 | $857 | $50 |
| Cholestyramine Light | 14 | $829 | $59 |
| Tamsulosin | 14 | $753 | $54 |
| Proctozone-Hc | 12 | $684 | $57 |
| Metoprolol | 13 | $640 | $49 |
| Gabapentin | 17 | $535 | $31 |
| Enalapril Maleate | 12 | $498 | $42 |
| Omeprazole | 29 | $319 | $11 |
| Triamterene-Hydrochlorothiazid | 16 | $312 | $20 |
| Lisinopril | 41 | $272 | $7 |
| Simvastatin | 20 | $197 | $10 |
| Finasteride | 11 | $188 | $17 |
| Glimepiride | 13 | $172 | $13 |
| Fluconazole | 11 | $168 | $15 |
| Metformin | 12 | $163 | $14 |
| Triamcinolone Acetonide | 11 | $158 | $14 |
| Terazosin | 13 | $155 | $12 |
| Losartan | 21 | $143 | $7 |
| Amlodipine Besylate | 29 | $122 | $4 |
| Alendronate | 14 | $110 | $8 |
| Hydrochlorothiazide | 15 | $68 | $5 |
| Furosemide | 19 | $37 | $2 |
2014: 22 drugs
| Nexium | 13 | $6,422 | $494 |
| Advair Diskus | 13 | $4,416 | $340 |
| Nasonex | 12 | $2,021 | $168 |
| Fluvastatin | 13 | $1,250 | $96 |
| Metoprolol | 22 | $1,051 | $48 |
| Atorvastatin | 36 | $753 | $21 |
| Cholestyramine Light | 13 | $681 | $52 |
| Levothyroxine | 26 | $558 | $21 |
| Proair Hfa | 11 | $523 | $48 |
| Diphenoxylate-Atropine | 12 | $322 | $27 |
| Enalapril Maleate | 25 | $274 | $11 |
| Triamterene-Hydrochlorothiazid | 15 | $245 | $16 |
| Amlodipine Besylate | 28 | $209 | $7 |
| Terazosin | 14 | $205 | $15 |
| Omeprazole | 11 | $175 | $16 |
| Metformin | 11 | $143 | $13 |
| Hydrochlorothiazide | 13 | $118 | $9 |
| Losartan | 11 | $90 | $8 |
| Simvastatin | 12 | $85 | $7 |
| Fluconazole | 11 | $56 | $5 |
| Trazodone | 13 | $49 | $4 |
| Alprazolam | 14 | $31 | $2 |
2013: 2 drugs
| Enalapril Maleate | 16 | $141 | $9 |
| Carvedilol | 12 | $95 | $8 |
Professional record
- NPI
- 1720168099
- Licence
- CA G64586California G64586: Current · expires 2028-09-30
- Trained
- University of California, San Francisco School of Medicine, 1987
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G645860
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-10-17
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.